# Formulary Change Starting October 1st, 2025, for ADHD Medication

[Impacted Members](#_Toc207267229)

[Communication to Members](#_Toc207267230)

[Key Changes](#_Toc207267231)

[Action Steps for Members](#_Toc207267232)

[Related Documents](#_Toc207267233)

**Description:** Information regarding the upcoming formulary change for ADHD medication, Vyvanse. This change will only impact select formularies (Caremark Standard/Choice formularies) and will not affect custom formularies. Agents should review this information during calls regarding the formulary change to assist members effectively.

|  |
| --- |
| Impacted Members |

 The Formulary Change for Vyvanse will take place on 10/01, rely on your tools to determine coverage for members:

* **Review the CIF**.
* **Run a test claim**

** Test Claims will not accurately reflect the formulary change until September 15, 2025, as the formulary coding will not be in place until that date. Starting on or after September 15, 2025, you will be able to future date test claims and receive accurate results before providing coverage details to ensure accurate information is communicated to members regarding formulary changes. Refer to [Compass - Test Claims (050041)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=60c20ea0-1d07-46e3-809a-b54734b80fbe), as needed.

* **Refer to and Utilize** [Compass - Viewing Communications (056371)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=c0238ae3-ea9b-4da2-b9c9-90c8d4ad62a8) to review member letters and educate accordingly.

**Aetna Commercial Members only:**To verify if this formulary change applies, Aetna CCRs must verify the member's formulary in GPS and then proceed to Aetna.com and locate the Drug guide changes for July 1 (PDF) on that formulary's page. Refer to [Aetna - GPS - Identifying Which Formulary Guide to Use for Commercial Members (068696)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=75c5286e-dbf7-4d23-9888-905d455765f3) and [Aetna - Medication Search Tool and Finding a Formulary (076129)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=fdd78993-fbca-42e9-b51b-a464c3c7e2cf) for additional changes as needed.

**For Questions and Answers regarding Standard Formulary Changes, refer to the following work instructions:**

**Compass Users:**[Compass - Standard Formulary Changes (065563)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=eea2c64c-d61c-4cd5-a2ab-444fcde92964)

**PeopleSafe Users:**[Standard Formulary Changes (114719)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=0afb51c4-054b-4d6e-b989-5aeefdb37145)

[Top of the Document](#_top)

|  |
| --- |
| Communication to Members |

* **Notification Letters:** Letters informing impacted members about the formulary change will be sent starting Friday, August 1st, 2025.
* **Letter Access:** Letters will be loaded into Compass for reference. Refer to [Compass - Viewing Communications (056371)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=c0238ae3-ea9b-4da2-b9c9-90c8d4ad62a8) for steps on viewing communications

[Top of the Document](#_top)

|  |
| --- |
| Key Changes |

* Vyvanse will be removed from the Caremark Standard/Choice formularies starting October 1st, 2025.
* Members with a current Prior Authorization or Exception for Vyvanse on their account will continue to have coverage for the duration of the Prior Authorization or Exception.
* The letters that will be received by members will be a standard letter template and will not indicate if the member has a Prior Authorization on file that they will continue to have coverage for the duration of the Prior Authorization, educate accordingly.

[Top of the Document](#_top)

|  |
| --- |
| Action Steps for Members |

* **Members currently filling Vyvanse with a Prior Authorization or Exception:** Educate the member that if they currently have a Prior Authorization or Exception on file for Vyvanse, no action is needed. They will continue to have coverage of Vyvanse for the duration of the Prior Authorization.
* **Members currently filling Vyvanse without a Prior Authorization or Exception:** As of 10/01, any member filling Vyvanse will either need to switch to the generic Lisdexamfetamine or talk to their doctor about other suitable alternatives.
* **Members currently not taking Vyvanse but are inquiring about coverage:** Run a test claim to determine coverage by the plan. If the medication is not covered by the plan, per test claim, educate the member that Vyvanse is not covered by the plan. Educate the member regarding the generic Lisdexamfetamine as an alternative to Vyvanse and run a test claim to determine coverage and cost of the generic. They will need to discuss any alternative with their doctor.

[Top of the Document](#_top)

|  |
| --- |
|  |

Perform the following steps:

|  |  |
| --- | --- |
| **Step** | **Action** |
| **1** | Ask the member if they received any communication about the changes. |
| **2** | Check the system for any letters sent regarding these formulary changes ([Compass - Viewing Communications (056371)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=c0238ae3-ea9b-4da2-b9c9-90c8d4ad62a8). |
| **3** | Review the member’s account for any current Prior Authorization on file for Vyvanse. |
| **4** | Educate the member on the duration of the Prior Authorization for Vyvanse and they will continue to have coverage for the duration of the Prior Authorization. |
| **5** | 1. Offer Lisdexamfetamine as cost effective alternative to discuss with their doctor.     A one-time override is allowed for members who are unable to locate the generic Lisdexamfetamine. Perform the following steps if the member is **unable to obtain the medication**:   * Confirm that the generic Lisdexamfetamine is not available at an in-network pharmacy. Refer to [Compass – Member Unable to Locate Medication at Mail Order or Retail (Back Order, Shortage, Not in Stock - NIS) (065451)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=47f1fc7c-d771-45ae-9de3-179ac312f222) or [Aetna Compass – Member Unable to Locate Medication at Mail Order or Retail (Back Order, Shortage, Not in Stock - NIS) (065602)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=1f690e4f-598d-4a35-9f4d-57f21728eaec). * Review the override history to ensure that the Manufacturer Backorder override has not been previously utilized for Vyvanse after 10/01.   + If the medication cannot be located **and** the Manufacturer Backorder override has not been utilized, contact the Senior Team to enter the one-time Manufacturer Backorder override for the brand Vyvanse for each strength the member is currently prescribed. Refer to [Compass - When to Transfer Calls to the Senior Team (057524)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=7653e7c2-1a97-42a0-8a81-6267c72e1ca9) or [Aetna - How and When to Contact the SRT (012811)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=35b41b78-3df9-419e-b3ce-5d184aeceb1e). * If a Manufacturer Backorder override has been entered after 10/01 for the Vyvanse, inform the caller that the one-time override has already been utilized. Offer the following alternatives: * Pay out-of-pocket for brand name Vyvanse. * Discount Card (**Example** GoodRx) or Manufacturer Copay Assistance Card. Refer to [Compass - Manufacturer Copay Assistance Cards (063965)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=8eb849ae-eaa3-4d01-bbf8-195b9cd4bdbf) or [Aetna Compass - Manufacturer Copay Assistance Cards (064369)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=6e0ca679-d161-4043-9206-334e7f4da5e1).  1. Speak with their doctor about other alternatives that may be suitable. |
| **6** | Run a Test Claim for the formulary change date of 10/01 or later to determine any possible cost changes for the member. Refer to [Compass – Test Claims (050041)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=60c20ea0-1d07-46e3-809a-b54734b80fbe).  Test Claims will not accurately reflect the formulary change until September 15, 2025, as the formulary coding will not be in place until that date. Starting on or after September 15, 2025, you will be able to future date test claims and receive accurate results. |
| **7** | Review the CIF for relevant information regarding custom formularies. |
| **8** | 1. Be prepared to answer questions regarding the transition and assist members in understanding the new process. 2. Ensure members understand the timeline and actions they need to take.   **Standard talking points in addressing member concerns regarding formulary changes:**   * **SMS Notifications:** If they are not already set up for SMS messaging, encourage the member to set up for Messaging Preferences. They will be notified 30 days ahead of time before their Prior Authorization expires. Refer to [Caremark.com – Prior Authorization (070305)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=20ba7691-5b2a-4780-9c3a-f671151ab55c). * **Caremark.com:** If the member is not registered on Carmark.com, offer to send a Quick Registration link to help them register. They can monitor their Prior Authorization on Caremark.com and it will inform the member if the Prior Authorization will be expiring soon. Refer to [Caremark.com – Prior Authorization (070305).](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=20ba7691-5b2a-4780-9c3a-f671151ab55c) * **Access to Medications:**CVS Caremark works diligently to ensure access to medications that are both clinically appropriate and cost-effective for our members and clients. * **Clinical Expertise:** We have a panel of independent clinical experts, including physicians and pharmacists, who assist us in determining which drugs to cover. This ensures that the options we provide are clinically appropriate and cost-effective for patients. * **Market Monitoring:** Our team is constantly monitoring the marketplace to deliver the best clinical and cost value possible. We encourage your doctor to review and consider all other formulary options available. * **Prior Authorization and Exceptions:** If the member does not currently have a prior authorization on file, educate on the generic option of Lisdexamfetamine. They will need to talk to their doctor regarding the best options available. After consultation with their doctor, depending on your plan, your doctor may be able to request prior authorization or an exception for coverage for Vyvanse, which will be reviewed on a case-by-case basis. |

[Top of the Document](#_top)

|  |
| --- |
| Related Documents |

[Formulary and URL Address Locations (051617)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=b8695466-1ae2-4ef2-a88f-d7e5795efd1f)

[Standard Formulary Changes (114719)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=0afb51c4-054b-4d6e-b989-5aeefdb37145)

[Aetna - Commercial Changes to Drug Lists / Formulary Updates FAQs  (010891)](https://thesource.cvshealth.com/nuxeo/thesource/#!/view?docid=12a95cea-1a70-41c8-83bf-b424b7578ab8)

**Parent Documents:**[CALL-0011 Authenticating Caller](https://policy.corp.cvscaremark.com/pnp/faces/DocRenderer?documentId=CALL-0011), [CALL 0049 Customer Care Internal and External Call Handling](https://policy.corp.cvscaremark.com/pnp/faces/DocRenderer?documentId=CALL-0049)

[Top of the Document](#_top)

Not To Be Reproduced Or Disclosed to Others Without Prior Written Approval

**ELECTRONIC DATA = OFFICIAL VERSION / PAPER COPY = INFORMATIONAL ONLY**